Veracyte Inc (VCYT) valuation
Veracyte P/E ratio history
Veracyte trades at 35.7 times its earnings over the last twelve months and 26.0 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $42.10 | $0.82 | 51.3 | 27.0 |
| Dec 31, 2024 | $39.60 | $0.31 | 127.7 | 54.1 |
| Dec 31, 2023 | $27.51 | -$1.02 | n/m | — |
| Dec 31, 2022 | $23.73 | -$0.51 | n/m | — |
| Dec 31, 2021 | $41.20 | -$1.11 | n/m | — |
| Dec 31, 2020 | $48.94 | -$0.68 | n/m | — |
| Dec 31, 2019 | $27.92 | -$0.28 | n/m | — |
| Dec 31, 2018 | $12.58 | -$0.63 | n/m | — |
| Dec 31, 2017 | $6.53 | -$0.91 | n/m | — |
| Dec 31, 2016 | $7.74 | -$1.08 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Veracyte valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| VeracyteVCYT | $3.99B | 35.7 | 26.0 | 7.1 |
| LiquidiaLQDA | $4.01B | 32.2 | 21.4 | 8.9 |
| Arcutis BiotherapeuticsARQT | $4.01B | 145.8 | 36.4 | 8.6 |
| Definium TherapeuticsDFTX | $3.96B | — | — | — |
| IrhythmIRTC | $4.05B | — | 137.3 | 4.9 |
| Icu MedicalICUI | $4.09B | 137.6 | 17.8 | 1.9 |
| CorvelCRVL | $4.17B | 36.5 | — | 4.2 |
| Indivior PharmaceuticalsINDV | $4.17B | 9.9 | 7.9 | 3.0 |
| Edgewise TherapeuticsEWTX | $4.18B | — | — | — |
| Peer median | 36.5 | 21.4 | 4.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: VCYT financials · VCYT returns
No forecast, no recommendation. This page describes Veracyte Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.